| SFRP2 promoter | ||||
---|---|---|---|---|---|
Variable | n a | Unmethylated (%) | Methylated (%) | R b | P c |
Total | 199 | 34 (17) | 165 (83) | Â | Â |
Clinicopathological factors | |||||
Age at diagnosis | Â | Â | Â | Â | Â |
   < 60 years | 114 | 24 (21) | 90 (79) | 0.122 | 0.091 |
   ≥ 60 years | 85 | 10 (12) | 75 (88) |  |  |
Tumor sized | Â | Â | Â | Â | Â |
   pT1 | 70 | 11 (16) | 59 (84) | -0.013 | 1.000 |
   pT2 – 4 | 114 | 19 (17) | 95 (83) |  |  |
Lymph node statusd | Â | Â | Â | Â | Â |
   pN0 | 89 | 19 (21) | 70 (79) | 0.129 | 0.106 |
   pN1 – 3 | 85 | 10 (12) | 75 (88) |  |  |
Histological grade | Â | Â | Â | Â | Â |
   G1 – G2 | 109 | 13 (12) | 96 (88) | -0.139 | 0.069 |
   G3 | 76 | 17 (22) | 59 (78) |  |  |
Histological type | Â | Â | Â | Â | Â |
   ductal | 155 | 26 (17) | 129 (83) | -0.057 | 0.434 |
   lobular | 24 | 1 (4) | 23 (96) |  |  |
   other | 14 | 5 (36) | 9 (64) |  |  |
Immunohistochemistry | |||||
Estrogen receptor | Â | Â | Â | Â | Â |
   negative (IRSe 0 – 2) | 64 | 13 (20) | 51 (80) | 0.084 | 0.295 |
   positive (IRS 3 – 12) | 123 | 17 (14) | 106 (86) |  |  |
Progesterone receptor | Â | Â | Â | Â | Â |
   negative (IRSe 0 – 2) | 70 | 14 (20) | 56 (80) | 0.083 | 0.304 |
   positive (IRS 3 – 12) | 117 | 16 (14) | 101 (86) |  |  |